Tin tức & Cập nhật
Xem bài viết Dược
Xem
Chỉ hiển thị Multimedia

How does baricitinib compare in RA patients at risk of VTE?
03 Jul 2026
bởiStephen Padilla
Treatment with baricitinib misses the noninferiority mark against tumour necrosis factor inhibitors (TNFi) in active rheumatoid arthritis (RA) patients at risk for venous thromboembolism (VTE) with high baseline disease activity, reports a study.
How does baricitinib compare in RA patients at risk of VTE?
03 Jul 2026
Novel extended-release tablet superior to febuxostat at reducing SUA levels
03 Jul 2026
bởiStephen Padilla
An extended-release formulation, HR091506, performs better than febuxostat immediate release in lowering urate levels in patients with gout and hyperuricaemia, as shown in a phase III trial.







